Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

被引：0
作者：
M. Tanioka
H. Nokihara
N. Yamamoto
Y. Yamada
K. Yamada
Y. Goto
T. Fujimoto
R. Sekiguchi
K. Uenaka
S. Callies
T. Tamura
机构：
[1] National Cancer Center Hospital,Division of Internal Medicine
[2] Eli Lilly Japan K.K.,undefined
[3] Eli Lilly and Company,undefined
[4] Erl Wood Manor,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 68卷
关键词：
Antisense oligonucleotide; Pharmacokinetics; Phase I; Survivin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：505 / 511
页数：6
相关论文
共 138 条
[81]  
Kornbrust DJ(undefined)undefined undefined undefined undefined-undefined
[82]  
Goel S(undefined)undefined undefined undefined undefined-undefined
[83]  
Desai K(undefined)undefined undefined undefined undefined-undefined
[84]  
Bulgaru A(undefined)undefined undefined undefined undefined-undefined
[85]  
Fields A(undefined)undefined undefined undefined undefined-undefined
[86]  
Goldberg G(undefined)undefined undefined undefined undefined-undefined
[87]  
Agrawal S(undefined)undefined undefined undefined undefined-undefined
[88]  
Martin R(undefined)undefined undefined undefined undefined-undefined
[89]  
Grindel M(undefined)undefined undefined undefined undefined-undefined
[90]  
Mani S(undefined)undefined undefined undefined undefined-undefined
45678910111213